![IACH on X: "Join us TODAY at 2pm Eastern Time (Atlanta), 8pm CET (Paris) for live news from #ASH21 with Dr. Salomon Manier and @Mohty_EBMT Register Free here: https://t.co/bdQmP2b0TS https://t.co/oYQD70BBZf" / X IACH on X: "Join us TODAY at 2pm Eastern Time (Atlanta), 8pm CET (Paris) for live news from #ASH21 with Dr. Salomon Manier and @Mohty_EBMT Register Free here: https://t.co/bdQmP2b0TS https://t.co/oYQD70BBZf" / X](https://pbs.twimg.com/media/FGeOEmnXIAMcmn9.jpg:large)
IACH on X: "Join us TODAY at 2pm Eastern Time (Atlanta), 8pm CET (Paris) for live news from #ASH21 with Dr. Salomon Manier and @Mohty_EBMT Register Free here: https://t.co/bdQmP2b0TS https://t.co/oYQD70BBZf" / X
![Optimal strategies to manage late-stage multiple myeloma: the promise of anti-BCMA therapies | VJHemOnc Optimal strategies to manage late-stage multiple myeloma: the promise of anti-BCMA therapies | VJHemOnc](https://i.ytimg.com/vi/Sz3rSPPTeK0/maxresdefault.jpg)
Optimal strategies to manage late-stage multiple myeloma: the promise of anti-BCMA therapies | VJHemOnc
![Hémopathies lymphoïdes et myéloïdes : quelles alternatives à l'hospitalisation en 2023 ? - Tribune'K Hemato Hémopathies lymphoïdes et myéloïdes : quelles alternatives à l'hospitalisation en 2023 ? - Tribune'K Hemato](https://www.tribunek-hemato.fr/wp-content/uploads/2023/07/KP_TKH_videos-debats-AH_MN-SM_Cover_11072023_V1.jpg)
Hémopathies lymphoïdes et myéloïdes : quelles alternatives à l'hospitalisation en 2023 ? - Tribune'K Hemato
![Manni Mohyuddin on X: "Excellent insights on t(14;16) in myeloma: https://t.co/hAAJW8rlLW n=107 (4% of entire cohort) Mostly co-exists with +1q and other abnormalities By itself v. rare, but may not be poor Manni Mohyuddin on X: "Excellent insights on t(14;16) in myeloma: https://t.co/hAAJW8rlLW n=107 (4% of entire cohort) Mostly co-exists with +1q and other abnormalities By itself v. rare, but may not be poor](https://pbs.twimg.com/media/F9XxtBDbgAAhza7.jpg)
Manni Mohyuddin on X: "Excellent insights on t(14;16) in myeloma: https://t.co/hAAJW8rlLW n=107 (4% of entire cohort) Mostly co-exists with +1q and other abnormalities By itself v. rare, but may not be poor
![Next generation sequencing identifies smoldering multiple myeloma patients with a high risk of disease progression - ecancer Next generation sequencing identifies smoldering multiple myeloma patients with a high risk of disease progression - ecancer](https://cdn.ecancer.org/35340-m.jpg)
Next generation sequencing identifies smoldering multiple myeloma patients with a high risk of disease progression - ecancer
![Myeloma Crowd Radio: Irene Ghobrial, MD & Salomon Manier, MD, PhD, Dana Farber 09/27 by HealthTree Podcast for MM | Health Myeloma Crowd Radio: Irene Ghobrial, MD & Salomon Manier, MD, PhD, Dana Farber 09/27 by HealthTree Podcast for MM | Health](https://dasg7xwmldix6.cloudfront.net/episodes/539173_RETPcwhp.jpg)